Graciotti Michele, Kandalaft Lana E
Center of Experimental Therapeutics, Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
Ludwig Institute for Cancer Research, Lausanne Branch, Lausanne, Switzerland.
Nat Rev Drug Discov. 2025 Feb;24(2):134-150. doi: 10.1038/s41573-024-01081-5. Epub 2024 Dec 2.
Improved understanding of cancer immunology has gradually brought increasing attention towards cancer-preventive vaccines as an important tool in the fight against cancer. The aim of this approach is to reduce cancer occurrence by inducing a specific immune response targeting tumours at an early stage before they can fully develop. The great advantage of preventive cancer vaccines lies in the potential to harness a less-compromised immune system in vaccine recipients before their immune responses become affected by the advanced status of the disease itself or by aggressive treatments such as chemotherapy. Successful implementation of immunoprevention against oncogenic viruses such as hepatitis B and papillomavirus has led to a dramatic decrease in virally induced cancers. Extending this approach to other cancers holds great promise but remains a major challenge. Here, we provide a comprehensive review of preclinical evidence supporting this approach, encouraging results from pioneering clinical studies as well as a discussion on the key aspects and open questions to address in order to design potent prophylactic cancer vaccines in the near future.
对癌症免疫学认识的不断提高,逐渐使癌症预防性疫苗作为对抗癌症的重要工具受到越来越多的关注。这种方法的目的是在肿瘤完全发展之前的早期阶段,通过诱导针对肿瘤的特异性免疫反应来减少癌症的发生。预防性癌症疫苗的巨大优势在于,在疫苗接种者的免疫反应受到疾病本身的晚期状态或化疗等积极治疗的影响之前,利用其相对未受损的免疫系统的潜力。成功实施针对乙型肝炎和乳头瘤病毒等致癌病毒的免疫预防,已导致病毒诱导的癌症显著减少。将这种方法扩展到其他癌症具有很大的前景,但仍然是一项重大挑战。在此,我们对支持这种方法的临床前证据、开创性临床研究的鼓舞人心的结果进行了全面综述,并讨论了在不久的将来设计有效的预防性癌症疫苗时需要解决的关键方面和开放性问题。